TITLE

Women's Health Issue -- Adverse Medication Effects

PUB. DATE
June 2011
SOURCE
Travel Medicine Advisor;Jun2011 Supplement, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers updates on health concerns in women in relation to medication effects in the U.S. The rituximab has been duly approved by the Food and Drug Administration (FDA) as an expanded indication to treat Wegener's granulomatosis and microscopic polyangiitis. It also confirms the smallest growth in pharmaceutical spending in 2000. On the other hand, the increased risk of venous thromboembolism (VTE) in women taking birth control pills with drospirenone is also mentioned.
ACCESSION #
61263594

 

Related Articles

  • Dynavax trial halted. DeFrancesco, Laura // Nature Biotechnology;May2008, Vol. 26 Issue 5, p484 

    This article reports that the U.S. Food and Drug Administration has halted a trial of Dynavax's hepatitis B vaccine Heplisav. The Heplisav trails were stopped in response to adverse effects of the drug reported in its third phase, which included Wegener's granulomatosis. The article discusses...

  • The Three-Month Injection.  // Time;5/31/1968, Vol. 91 Issue 22, p57 

    The article reports on the plan of Upjohn Co. to start marketing its Depo-Provera injectable contraceptive drug if the U.S. Food and Drug Administration (FDA) approves it. It notes that Depo-Provera can treat uterine disorders, however, it can cause infertility that lasts one year or more. It...

  • The Safe and Effective Pills.  // Time;8/19/1966, Vol. 88 Issue 8, p61 

    The article discusses the advantage and disadvantage of using oral contraceptives as stated by the U.S. Food and Drug Administration (FDA). The FDA reported that the pills are 99 percent effective with no major side effects. It states that the pills were alleged to be the cause of some...

  • What's new in drugs. Rodman, Morton J. // RN;Mar77, Vol. 40 Issue 3, p33 

    Reports on the decision of the U.S. Food and Drug Administration to revise the labeling of estrogen-containing products, including oral contraceptives. Health risks posed by the estrogen-based drugs; Recommended way to administer the drugs; Advice to patients.

  • Bitter Pill. Kennedy, John W. // Christianity Today;Feb2005, Vol. 49 Issue 2, p23 

    Deals with the move of the U.S. Food and Drug Administration (FDA) to strengthen warning on RU-486, an abortion inducing drug also called mifepristone. Reason for the move of the FDA; Allegation by the Christian Medical Association (CMA) that the FDA failed to follow standard procedural and...

  • FDA actions. Elliott, William T. // Infectious Disease Alert;Jun2011 Pharmacology Watch, p2 

    The article reports on the U.S. Food and Drug Administration's (FDA) approval of the drugs, rituximab (Rituxan) by Genentech for the treatment of Wegener's granulomatosis and microscopic polyangiitis and gabapentin enacarbil for the treatment of restless leg syndrome.

  • FDA actions. Elliott, William T. // Neurology Alert;Jun2011 Primary Care, p2 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved rituximab, branded as Rituxan, for the expanded indication to treat Wegener's granulomatosis and microscopic polyangiitis and gabapentin enacarbil for the treatment of moderate-to-severe restless leg syndrome.

  • The Pill: A New Warning.  // Time;9/8/1975, Vol. 106 Issue 10, p66 

    The article reports that women aged 30- 40 years old who are taking oral contraceptive pill are wanred on the risk of heart attacks. It says that pills can trigger thrombophlebitis, a blood clot forming in the legs that may result to pulmonary embolism once it reached the lungs. It mentions that...

  • Estradiol valerate, dienogest OC gets nod.  // Contraceptive Technology Update;Sep2010, Vol. 31 Issue 9, p100 

    The article discusses the approval of the oral contraceptive Natazia (estradiol valerate) by the U.S. Food and Drug Administration (FDA).

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics